KRSNAA DIAGNOSTICS share price has zoomed 6% and is presently trading at Rs 826.5.
Meanwhile, the BSE HEALTHCARE index is at 43,953.5 (up 1.9%).
Among the top gainers in the BSE HEALTHCARE index today are Jubilant Pharmova (up 6.5%) and GSK Pharma (up 4.4%).
ASTRAZENECA PHARMA (down 1.0%) and Pfizer (down 0.4%) are among the top losers today.
Over the last one year, KRSNAA DIAGNOSTICS has moved up from Rs 678.4 to Rs 826.5, registering a gain of Rs 148.2 (up 21.8%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,012.1 to 43,953.5, registering a gain of 56.9% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 166.6%), Glenmark Pharma (up 114.8%) and SUVEN PHARMACEUTICALS (up 109.7%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 81,634.8 (up 0.7%).
The top gainers among the BSE Sensex today are MUNDRA PORT & SEZ (up 4.8%) and M&M (up 3.4%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 25,013.2 . TATA STEEL 2% CCPS and Dr Reddy NCD1 are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,226.0 to 81,634.8, registering a gain of 16,408.8 points (up 25.2%).
KRSNAA DIAGNOSTICS net profit grew 22.4% YoY to Rs 179 million for the quarter ended June 2024, compared to a profit of Rs 146 million a year ago. Net sales rose 22.0% to Rs 1,702 million during the period as against Rs 1,396 million in April-June 2023.
For the year ended March 2024, KRSNAA DIAGNOSTICS reported 8.5% decrease in net profit to Rs 568 million compared to net profit of Rs 621 million during FY23. Revenue of the company grew 27.2% to Rs 6,196 million during FY24.
The current Price to earnings ratio of KRSNAA DIAGNOSTICS, based on rolling 12 month earnings, stands at 44.4.
Equitymaster requests your view! Post a comment on "KRSNAA DIAGNOSTICS Gains 6%; BSE HEALTHCARE Index Up 1.9%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!